文献速递间质性肺疾病

CXCL14是特发性肺纤维化中Hedgehog信号通路的候选生物标志物

CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosis.
PubMed 文献 · Thorax · 2017-03-01

该研究通过检测IPF患者与对照的肺活检、小鼠肺、体外SHh刺激的成纤维细胞及血浆,发现IPF肺组织和血浆中CXCL14表达显著升高,且vismodegib治疗可降低癌症患者循环CXCL14水平,提示CXCL14可作为监测IPF中Hh通路活性的全身性生物标志物。

要点

  • IPF患者肺组织和血浆中CXCL14表达显著升高,与Hh通路活性相关。
  • vismodegib可抑制CXCL14表达,提示其可监测Hh拮抗剂药效。
  • CXCL14有望作为IPF中Hh通路活性的非侵入性生物标志物。

核心结论

  • CXCL14是一种全身性生物标志物,可用于识别Hh通路活性增高的IPF患者并监测Hh拮抗剂治疗的药效学效应。

研究设计与样本

  • 研究评估了IPF与对照肺活检、小鼠肺、体外SHh刺激的成纤维细胞以及IPF患者与对照、癌症患者接受vismodegib治疗前后的血浆中的基因和蛋白表达。

主要发现

  • IPF患者肺组织Hh相关基因表达显著高于对照。
  • IPF肺活检和体外SHh刺激的成纤维细胞中上调最显著的基因是CXCL14,vismodegib体外可抑制其表达。
  • 小鼠肺中SHh过表达可诱导CXCL14表达。
  • IPF患者血浆循环CXCL14蛋白水平显著高于对照。
  • 癌症患者接受vismodegib治疗后循环CXCL14水平显著降低。

临床怎么用

  • CXCL14可能用于识别Hh通路活性增高的IPF患者,并监测Hh拮抗剂治疗的药效学效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is associated with aberrant expression of developmental pathways, including Hedgehog (Hh). As Hh signalling contributes to multiple pro-fibrotic processes, Hh inhibition may represent a therapeutic option for IPF. However, no non-invasive biomarkers are available to monitor lung Hh activity. METHODS: We assessed gene and protein expression in IPF and control lung biopsies, mouse lung, fibroblasts stimulated in vitro with sonic hedgehog (SHh), and plasma in IPF patients versus controls, and cancer patients before and after treatment with vismodegib, a Hh inhibitor. RESULTS: Lung tissue from IPF patients exhibited significantly greater expression of Hh-related genes versus controls. The gene most significantly upregulated in both IPF lung biopsies and fibroblasts stimulated in vitro with SHh was CXCL14, which encodes a soluble secreted chemokine whose expression is inhibited in vitro by the addition of vismodegib. CXCL14 expression was induced by SHh overexpression in mouse lung. Circulating CXCL14 protein levels were significantly higher in plasma from IPF patients than controls. In cancer patients, circulating CXCL14 levels were significantly reduced upon vismodegib treatment. CONCLUSIONS: CXCL14 is a systemic biomarker that could be used to identify IPF patients with increased Hh pathway activity and monitor the pharmacodynamic effects of Hh antagonist therapy in IPF. TRIAL REGISTRATION NUMBER: Post-results, NCT00968981.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Jia G, Chandriani S, Abbas AR, et al. CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosis. Thorax. 2017. PMID: 28250200. doi:10.1136/thoraxjnl-2015-207682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。